Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2018 16:15 ET | Source: Aduro Biotech, Inc.

Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies

INDIANAPOLIS and BERKLEY, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive...
December 12, 2018 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity

BERKELEY, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the publication of a peer-reviewed paper in Cell Reports authored by Aduro scientists and...
December 03, 2018 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition

BERKELEY, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data in two abstracts for its first-in-class anti-APRIL antibody BION-1301...
November 09, 2018 07:30 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas

Data presented at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting demonstrate ADU-S100 (MIW815) is well-tolerated with no dose-limiting toxicities reported Preliminary signs of...
November 06, 2018 16:16 ET | Source: Aduro Biotech, Inc.

Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

BERKELEY, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the company will host and webcast an investor event on Friday, November 9, 2018 at 6:30...
October 30, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Reports Third Quarter 2018 Financial Results

BERKELEY, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the third quarter ended September 30, 2018. Net loss for the third quarter...
October 26, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Presents Preclinical Data for Anti-APRIL Antibody BION-1301 for the Treatment of IgA Nephropathy at ASN Kidney Week 2018

BERKELEY, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data for its first-in-class anti-APRIL antibody BION-1301 supporting its use in the...
October 01, 2018 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Four Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

BERKELEY, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that four separate abstracts from its research and development portfolio will be presented at...
September 25, 2018 16:45 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at Two Investor Conferences in October

BERKELEY, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present...
September 19, 2018 09:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces the Departure of Natalie R. Sacks, M.D.

BERKELEY, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Natalie R. Sacks, M.D. has resigned from her position as the company’s chief medical...